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EDITORIAL
What’s up in nuclear medicine?
Peter J Ell
Institute of Nuclear Medicine, University College London, UK
Well, a lot of it. SPET/CT and indeed PET/CT have
arrived, and we are witnessing the first applications.
Instantaneous image fusion, accurate co-registration, and
often reduced imaging times are real benefits. The
world of radiotherapy planning may change forever—
who knows how intensity modulated radiation therapy
will change and benefit from routinely available PET/CT?
Of course all of this presents us with new opportunities,
challenges and training development. But the buzz is
here, and here to stay for a number of years. Oh yes,
I’ve heard it all before, in the 70s, 80s, and 90s, that
nuclear medicine is about to fall off the plane—a little like
MRI pushing CT off balance—and look what has really
happened . . .
In the meantime the reader would be well advised to
not just read but to carefully consider the article written
in Scientific American in its October 2001 issue. Simply
entitled ‘Magic bullets fly again’, it describes the real
progress achieved with labelled monoclonal antibodies
now available to treat lymphoma. A large number of these
have or are about to obtain FDA approval for large-scale
application in a variety of cancers. Rituximab may exceed
the one billion dollar market—the first such antibody to
pass this milestone.
In the meantime many of us are still busy with the
sentinel lymph node approach in the management of
the surgical and oncological patient. The next world
conference in Yokohama will attract over 1000 attendees,
all engaged in this application of the radioactive tracer.
Melanoma, ca breast, head and neck, gynaecological ca,
oesophageal ca, will all be subject to intense debate. And
yes, nuclear medicine has raised the level of debate: on
what is the standard of care in respect to axillary lymph
node dissections, or extensive basin dissections when the
sentinel node is clearly negative? Nuclear medicine has
offered new opportunities for pathologists to focus their
efforts on a few preselected nodes rather than on a large
number of randomly sampled ones . . . And the discussion
rages between H&E,IHC,PCR, and all because a tiny
amount of labelled colloid allows you to take out the
villain in question . . .
And so that I do not forget, many of us are also engaged
in the study of movement disorders and making use of
the new ligand for the dopamine transporter, an I-123
labelled compound recently introduced in the UK market.
Indeed the buzz is here, and here to stay . . .
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